At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
BMS-986166 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating BMS-986166, Branebrutinib, and 1 other intervention for Dermatitis, Atopic. Completed, enrolled 17 participants across 42 sites in 7 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesAustralia, Austria, Canada, Germany, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartAug 2021
First PostedAug 2021
Primary CompletionAug 2022
TodayJul 2026
First PostedAug 20, 2021
Enrollment StartAug 17, 2021
Primary CompletionAug 22, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.9 years ago
Interventions
BMS-986166drug
Specified dose on specified days
Branebrutinibdrug
Specified dose on specified days
Placeboother
Specified dose on specified days